Volumen: 19 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2015
Ponatinib and bosutinib:
new tyrosine kinasa inhibitors.
Authors: Bendek Del Prete, G.
Abstract: The treatment of chronic myeloid leukemia (CML)
must be considered as one of the great medical successes
of the last 30 years. Progression to accelerated
phase or blast crisis or resistance to first-line
treatment reduced the survival of these patients. The
selection of the second line of treatment depends
on which TKI the patient has previously received,
comorbidities and the presence or absence of BCRABL1
mutations. Bosutinib, a second generation
TKI, is approved for patients with CML in any of
its phases, with intolerance o resistance to previous
treatment with another TKI. It’s the T315I mutation
that confers increased resistance to imatinib, nilotinib
and dasatinib, and is associated with disease
progression and poor prognosis. Ponatinib is a potent,
orally active TKI against mutated and non-mutated
BCR-ABL1, including the T315I mutation.
Key words: Chronic myeloid leukemia,
Bosutinib,
T315I mutation,
Ponatinib.
Pages :
|
